Abbott Laboratories – Medical Device Offerings & GPO Relationships

  • Multi Asset
  • Healthcare
  • North America


Former VP at Abbott Laboratories Inc


  • Trends and themes in the medical device industry, focusing on Abbott Laboratories (NYSE: ABT)
  • Supply chain inefficiencies from coronavirus and impact on manufacturing operations
  • Abbott's GPO (global purchasing organisation) relationships and importance to commercial performance
  • Competitive landscape – Abbott vs Boston Scientific (NYSE: BSX), Edwards Lifesciences (NYSE: EW) and Medtronic (NYSE: MDT)
  • Q1 2022 outlook, growth expectations and potential M&A


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 25,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited